Dusquetide demonstrates positive anti-tumor efficacy in multiple nonclinical animal studies

Princeton, n.j., jan. 4, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that dusquetide is effective at reducing tumor size in nonclinical xenograft models.
SNGX Ratings Summary
SNGX Quant Ranking